|
FOCUS ON FACILITIES DESIGN |
|
|
|
By Better Biopharma Podcast | In this episode of "Better Biopharma," host Tyler Menichiello is joined by Tonix Pharmaceuticals' chief technical officer, Siobhan Fogarty, to discuss the planning and construction of its manufacturing facility in Dartmouth, MA, which was purpose-built for the production of its horsepox-based live viral vaccine platform, TNX-801. | |
|
|
|
|
| High Power Mixing At Large Scale: An Overview Of A Magnetic Mixer | Poster | By Arnaud de Boulard, Eric Corti, Mustapha Hohoud, and Nagaraj Rao, Cytiva | Explore the advantages of 2000 and 3000 L single-use mixing systems and experimental results demonstrating their capacity to deliver high power at large scales and flexibility for use at lower volumes. |
|
|
|
| Portable Tube Welders Vs. Fixed Systems In Biopharma | Article | Ensorcell | As manufacturing becomes more flexible and decentralized, sterile connection choices matter more than ever. Examine how portable and fixed tube welders compare and how each supports sterility. |
|
|
FACILITIES DESIGN SOLUTIONS |
|
|
|
|
|
|
FOCUS ON MANUFACTURING CONTROLS |
|
|
|
|
|
| Digitalizing Batch Records In Pharmaceutical Production | Case Study | By Gokhul Srinivasan, AWS, and Lluis Solanes, Aizon | Pharma manufacturing embraces cutting-edge automation, yet outdated paper-based documentation hinders efficiency. Take a look at how digital solutions can transform compliance. |
|
|
| How Can Custom Automation Accelerate Commercialization? | Article | By Domink Bell, Tecan | Moving from benchtop success to broader use requires scalability. Laboratory automation can reduce variability, improve control, and create a more efficient path toward commercial-ready solutions. |
|
|
| For Greater Transparency And Efficiency | White Paper | Siemens | Paper-heavy production can slow decisions and limit flexibility. Find out how IT/OT integration connects shop-floor and enterprise data to support real-time visibility and more resilient operations. |
|
|
|
| From DNA To IND In As Little As 6 Months | Webinar | Lonza | Observe how an integrated, platform-driven CMC approach can accelerate your antibody program from DNA to IND in as little as six months while reducing risk and maintaining quality and regulatory alignment. |
|
|
|
MANUFACTURING CONTROLS SOLUTIONS |
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|